REVB: Development spending rose as cash runway fell short of one year

Q3 and 9M operating expenses and losses increased YoY as development spending rose, led by GEM-AKI. Cash of $9.1M is not expected to fund operations for a year after issuance, making additional financing critical.

Original document: Revelation Biosciences, Inc. [REVB] SEC 10-Q Quarterly Report — Nov. 5 2026